Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.
Kai H, Morioka Y, Murashi T, Morita K, Shinonome S, Nakazato H, Kawamoto K, Hanasaki K, Takahashi F, Mihara S, Arai T, Abe K, Okabe H, Baba T, Yoshikawa T, Takenaka H. Kai H, et al. Among authors: arai t. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4030-4. doi: 10.1016/j.bmcl.2007.04.093. Epub 2007 Apr 30. Bioorg Med Chem Lett. 2007. PMID: 17521907
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: arai t. J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39762722
Successful treatment with bortezomib for refractory cryoglobulinemic vasculitis triggered by ischemic non-obstructive coronary artery disease.
Ohta Y, Tsuchiya T, Oka M, Tachibana M, Kondo Y, Fukushima K, Matsuno S, Yamanaka N, Suzuki N, Komatsu A, Rokutan H, Yumura W, Arai T, Ishigami A, Itabashi M, Takei T. Ohta Y, et al. Among authors: arai t. CEN Case Rep. 2025 Jan 6. doi: 10.1007/s13730-024-00963-2. Online ahead of print. CEN Case Rep. 2025. PMID: 39760978 Free article.
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb.
Nakano T, Okita K, Okazaki S, Yoshimoto S, Masuko S, Yagi H, Kato K, Tomioka Y, Imai K, Hamada Y, Masuko K, Shimada-Takaura K, Nagai N, Saya H, Arai T, Ishiwata T, Masuko T. Nakano T, et al. Among authors: arai t. FEBS Open Bio. 2025 Jan 5. doi: 10.1002/2211-5463.13963. Online ahead of print. FEBS Open Bio. 2025. PMID: 39757718 Free article.
4,172 results